US Patent 11510997 Treatment of primary ciliary dyskinesia with synthetic messenger RNA
Patent 11510997 was granted and assigned to TranscripTx, Inc. on November, 2022 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 11510997 Treatment of primary ciliary dyskinesia with synthetic messenger RNA
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.